Literature DB >> 30086863

Management of hypogonadism from birth to adolescence.

Sasha R Howard1, Leo Dunkel2.   

Abstract

Management of patients with hypogonadism is dependent on the underlying cause. Whilst functional hypogonadism presenting as delayed puberty in adolescence is relatively common, permanent hypogonadism presenting in infancy or adolescence is unusual. The main differential diagnoses of delayed puberty include self-limited delayed puberty (DP), idiopathic hypogonadotropic hypogonadism (IHH) and hypergonadotropic hypogonadism. Treatment of self-limited DP involves expectant observation or short courses of low dose sex steroid supplementation. More complex and involved management is required in permanent hypogonadism to achieve both development of secondary sexual characteristics and to maximize the potential for fertility. This review will cover the options for management involving sex steroid or gonadotropin therapy, with discussion of benefits, limitations and specific considerations of the different treatment options.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  estradiol; gonadotropin therapy; hypogonadism; puberty; rFSH; testosterone

Mesh:

Substances:

Year:  2018        PMID: 30086863     DOI: 10.1016/j.beem.2018.05.011

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  8 in total

1.  An Indonesian male with congenital hypogonadotropic hypogonadism: A case report and literature review.

Authors:  Leadri Surya Arrosy; Hermina Novida
Journal:  Ann Med Surg (Lond)       Date:  2022-09-15

Review 2.  Congenital Hypogonadotrophic Hypogonadism: Minipuberty and the Case for Neonatal Diagnosis.

Authors:  Du Soon Swee; Richard Quinton
Journal:  Front Endocrinol (Lausanne)       Date:  2019-02-21       Impact factor: 5.555

3.  Cisplatin and carboplatin result in similar gonadotoxicity in immature human testis with implications for fertility preservation in childhood cancer.

Authors:  Melissa D Tharmalingam; Gabriele Matilionyte; William H B Wallace; Jan-Bernd Stukenborg; Kirsi Jahnukainen; Elizabeth Oliver; Anne Goriely; Sheila Lane; Jingtao Guo; Bradley Cairns; Anne Jorgensen; Caroline M Allen; Federica Lopes; Richard A Anderson; Norah Spears; Rod T Mitchell
Journal:  BMC Med       Date:  2020-12-04       Impact factor: 8.775

Review 4.  The impact of male factors and their correct and early diagnosis in the infertile couple's pathway: 2021 perspectives.

Authors:  F Pallotti; A Barbonetti; G Rastrelli; D Santi; G Corona; F Lombardo
Journal:  J Endocrinol Invest       Date:  2022-03-29       Impact factor: 5.467

5.  Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the Management of Endocrine Complications in Patients with Haemoglobinopathies.

Authors:  Maddalena Casale; Marina Itala Baldini; Patrizia Del Monte; Antonia Gigante; Anna Grandone; Raffaella Origa; Maurizio Poggi; Franco Gadda; Rosalba Lai; Monia Marchetti; Gian Luca Forni
Journal:  J Clin Med       Date:  2022-03-25       Impact factor: 4.241

6.  Identification and Functional Characterization of a Novel Variant in the SEMA3A Gene in a Chinese Family with Kallmann Syndrome.

Authors:  Meng Shu; Huixiao Wu; Shuoshuo Wei; Yingzhou Shi; Zongyue Li; Yiping Cheng; Li Fang; Chao Xu
Journal:  Int J Endocrinol       Date:  2022-10-11       Impact factor: 2.803

Review 7.  Stem Leydig Cells in the Adult Testis: Characterization, Regulation and Potential Applications.

Authors:  Panpan Chen; Barry R Zirkin; Haolin Chen
Journal:  Endocr Rev       Date:  2020-02-01       Impact factor: 19.871

Review 8.  Interpretation of reproductive hormones before, during and after the pubertal transition-Identifying health and disordered puberty.

Authors:  Sasha R Howard
Journal:  Clin Endocrinol (Oxf)       Date:  2021-08-08       Impact factor: 3.523

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.